NCT05301842 2026-04-07
EMERALD-3
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
10 trialsNCT03937830 2026-03-24
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT06608940 2026-02-19
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
Case Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT05883644 2026-02-18
SIERRA
AstraZeneca
Phase 3 Active not recruiting
NCT06855225 2026-01-14
A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
Hoosier Cancer Research Network
Phase 2 Not yet recruiting
NCT05701488 2025-09-02
SIRT With Tremelimumab and Durvalumab for Resectable HCC
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT05451043 2025-06-26
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT04988945 2023-09-06
TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma
The University of Hong Kong
Phase 2 Recruiting
NCT02821754 2023-03-28
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01853618 2019-12-10
Tremelimumab With Chemoembolization or Ablation for Liver Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed